Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit
“The strength of the HERIZON-GEA-01 data firmly positions Ziihera as the HER2-targeted agent-of-choice capable of reshaping first-line treatment for HER2+ metastatic GEA patients,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. “These results signal a clear evolution beyond the current standards and give us strong conviction as we move rapidly toward FDA submission. We are equally energized by the momentum we see across our broader development program, and we continue to evaluate Ziihera in multiple HER2-driven tumor types, including in HER2+ metastatic breast cancer with the ongoing Phase 3 EmpowHER-303 trial. This is the kind of scientific advancement that can redefine outcomes for patients, and we are committed to delivering it with urgency.”
Share:
More News
“From the outset, our goal has been to build a discovery engine that systematically unlocks high-value, challenging targets and delivers first-in-class precision medicines,” said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares. “This collaboration lets us scale that engine alongside Novartis’ world-class development capabilities and global reach, so we
“We are very pleased that the iDMC has recommended continuation of the landmark OVATION 3 clinical trial without modification, representing another important validation of the remarkable efficacy and safety data previously reported and further indicating the potential for IMNN-001 to represent a historic advance in the treatment of ovarian cancer,”
“VS-7375 has demonstrated anti-tumor activity across multiple dose levels and tumor types, encouraging signals from rational combination strategies, and a favorable safety profile that improves meaningfully beyond the first treatment cycle, underscoring its potential to be not only the best-in-class oral KRAS G12D inhibitor, but also the preferred treatment option
“We are pleased that the FDA has demonstrated urgency in reconsidering the RP1 BLA with an expeditious action date in recognition of the significant unmet need for advanced melanoma patients and support from the broader melanoma community,” said Sushil Patel, Ph.D., CEO of Replimune. “We look forward to a productive